beplay苹果手机能用吗研究人员寻求志愿者进行COVID-19疫苗研究
三期临床试验,评估能力l vaccine is effective at preventing symptomatic COVID-19 is now open for enrollment by The University of Texas Health Science Center at Houston (Uthealth) in collaboration with纪念赫尔曼 - 德克萨斯医疗中心。
研究疫苗，阿斯利康的AZD1222已显示早期人类试验to produce a positive immune response. This trial seeks to enroll 30,000 individuals across the nation. The Houston research site is theUthealth临床研究部门beplay苹果手机能用吗at Memorial Hermann-Texas Medical Center.
“The global infectious disease research community has united to launch numerous research studies as we search for treatment and prevention strategies for this illness. The development of a vaccine for COVID-19 is a critical step to help us return to normal,” saidRoberto C. Arduino，医学博士, the study’s lead investigator and professor ofinfectious disease在Uthealth的McGovern医学院。
参与者必须年满18岁，健康或患有医学稳定的慢性疾病，没有SARS-COV-2感染的已知史，并且感染风险增加。例如，其中包括具有稳定的基础医疗状况的人，在工作中遭受高风险的人，65岁以上的人，老年护理设施的居民或来自种族和族裔的个人，这些人受到更多影响的人。大流行，例如非裔美国人，拉丁裔和美洲原住民。
试验参与者将分两剂相隔四个星期的两剂实验疫苗或安慰剂（无菌盐水）。初步的datahas suggested that a single dose can provoke the two main mechanisms of the adaptive immune system – the humoral and cellular immune responses.
体液免疫也被称为抗体介导的免疫，如果该人在接种后与病毒接触，则可以攻击攻击SARS-COV-2的抗体。细胞免疫依赖于T淋巴细胞（白细胞）来攻击感染SARS-COV-2病毒的细胞。T淋巴细胞（通常称为T细胞）负责赋予长期免疫记忆。自适应免疫是通过感染或疫苗接种获得的。早期研究还表明，在第beplay苹果手机能用吗二剂疫苗后，人体的抗体反应得到了增强。
参与者将以2：1的比率随机分配，大约有20,000名参与者接受两剂AZD1222疫苗，10,000剂接受两剂安慰剂。该试验是双盲的，这意味着患者和研究人员都不知道将哪些研究组参与者放入。beplay苹果手机能用吗
该疫苗是由牛津大学开发的，由黑猩猩腺病毒的弱化和不复制版本组成，导致普通感冒，其中包含编码SARS-COV-2病毒峰值蛋白的遗传材料。该表面蛋白使冠状病毒具有冠状外观，并使其连接到并进入细胞。研究疫苗旨在促进针对峰值蛋白的抗体的开发，并防止其进入细胞。
“This vaccine study is pivotal toward controlling the COVID-19 pandemic and it’s important that we reach out to the members of our community who have been especially impacted by this illness,” saidJonatan Gioia, MD，UTHbeplay苹果手机能用吗ealth McGovern医学院的研究助理和试验的项目经理。McGovern医学院的其他共同投资者包括医学博士Carmel B. Dyer和MS MD的Jessica Lee。
For more information on this trial visitClinicaltrials.gov，或电子邮件COVID19vaccinestudy@uth.tmc.edu。
To enroll in this trial visithttps://www.coronaviruspreventionnetwork.org/clinical-study-volunteer/(Site code:HART).
The National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health, and the Biomedical Advanced Research and Development Authority (BARDA), part of the U.S. Department of Health and Human Services’ Office of the Assistant Secretary for Preparedness and Response, are providing funding support for the trial.